We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.50 | 0.21% | 1,644.00 | 1,644.00 | 1,644.50 | 1,647.00 | 1,635.00 | 1,638.50 | 185,752 | 08:34:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
Date | Subject | Author | Discuss |
---|---|---|---|
29/3/2015 17:40 | Couldn't agree more Philo - just me putting my foot in it. Apologies all. NR | nik rosa | |
29/3/2015 14:54 | Great news for kids. | philo124 | |
29/3/2015 14:28 | Only great news if GSK didn't compromise too much on the price! Monday's trading will reveal. NR | nik rosa | |
29/3/2015 14:25 | Great news re Hepatitis B Vaccines. | philo124 | |
29/3/2015 13:55 | No info as yet. May hear more at AGM 7th May. | sicker | |
29/3/2015 12:44 | when is the £4bn special dividend happening? | zyzzyva | |
27/3/2015 23:54 | 'Even After Recent Gains, AstraZeneca plc And GlaxoSmithKline plc Are Still Cheap' | philanderer | |
27/3/2015 13:36 | Ebola vaccine candidates pass safety test in Liberia trials | philanderer | |
26/3/2015 09:19 | GlaxoSmithKline : Glaxo Gets Approval For Encruse Ellipta, Two Other Products In Japan | philanderer | |
26/3/2015 08:57 | I wonder how many sellers pre end tax year, who will turn buyers after April 6th? | madengland | |
25/3/2015 23:50 | That quote doesn't make much sense does it? "They currently have a $42.00 price target on the stock. Zacks‘s price objective would indicate a potential downside of 11.30% from the company’s current price." How exactly is $42 LESS than the current price?!? In any event that same article also says, further on: "Seven analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $47.00." | woodhawk | |
25/3/2015 23:09 | Evening Woodhawk, nope not short , have never shorted a stock, just indices. Long GSK from 1375p 'GlaxoSmithKline plc Stock Rating Reaffirmed by Zacks (GSK)' GlaxoSmithKline plc (NYSE:GSK)‘s stock had its “hold” rating restated by Zacks in a research report issued on Wednesday. They currently have a $42.00 price target on the stock. Zacks‘s price objective would indicate a potential downside of 11.30% from the company’s current price. Zacks’ analyst wrote, “Glaxo’s fourth-quarter results were disappointing with the company posting a year-over-year decline in both revenues and earnings. However, the company has resolved most of the supply issues that it was facing over the last few quarters. We are positive on Glaxo’s restructuring and divestment plans, which should make it more cost efficient. Moreover, Glaxo’s deal with Novartis should boost its consumer health business. Meanwhile, challenges remain in the form of increasing competition, genericization and pricing pressure. Moreover, primary care contracting and pricing dynamics will continue to impact the performance of the respiratory segment.” | philanderer | |
25/3/2015 15:22 | Analysts are the same as the weather forecaster--they know what will happen if all their assumptions are fulfilled. Of course when these are not, then they produce a new set of assumptions ad nauseum. 1350p!!!! They are a few weeks out of date are they not? | jadeticl3 | |
25/3/2015 12:40 | That's a well-timed bit of doom there, philanderer, just as the share price threatens to drop below £16.00. You short? | woodhawk | |
25/3/2015 09:18 | This kind of PR goes down much better in the US, even for a British company! | tradermichael | |
25/3/2015 09:16 | They should, and maybe they do although have not seen any evidence/publicity/s | cyberian | |
25/3/2015 09:03 | But do they run these programmes in the UK? | tradermichael | |
25/3/2015 08:47 | Looking back over the last 5 years it appears that the share price tends to rise after April 5th tax year-end, and hopefully will happen this year with a lot of reasonable expectations from the company. The firm USD may help matters, and the dividend remains very attractive given the expectation of continuing low or even negative interest rates. I was delighted to see the GSK initiative being expanded in the USA over a commitment in a number of States for school holiday sessions on science etc....the sessions seem like a lot of fun and very well organised. I wish more majors would increase these types of programs...good PR but also great for motivating the young potential stars of the future. | cyberian | |
25/3/2015 08:26 | Well I hope it relaxes until I receive my 23p/share dividend on 9 April, then I'll steam in for some more. | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions